Small Vessel Disease Is Associated with Tissue Inhibitor of Matrix Metalloproteinase-4 After Ischaemic Stroke.


Journal

Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297

Informations de publication

Date de publication:
02 2019
Historique:
received: 19 01 2018
accepted: 27 03 2018
revised: 25 03 2018
pubmed: 25 4 2018
medline: 16 4 2019
entrez: 25 4 2018
Statut: ppublish

Résumé

Small vessel disease (SVD) is frequent in aging and stroke patients. Inflammation and remodeling of extracellular matrix have been suggested as concurrent mechanisms of SVD. We investigated the relationship between imaging features of SVD and circulating metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in patients with ischaemic stroke. In patients treated with intravenous thrombolysis, we took blood samples before intravenous thrombolysis and 90 days after the acute stroke and analysed levels of MMPs and TIMPs. We assessed leukoaraiosis, number of lacunes and brain atrophy on pre-treatment CT scan and graded global SVD burden combining such features. We investigated associations between single features, global SVD and MMPs and TIMPs at baseline and at follow-up, retaining univariate statistically significant associations in multivariate linear regression analysis and adjusting for clinical confounders. A total of 255 patients [mean (±SD) = 68.6 (± 12.7) years, 154 (59%) males] were included, 107 (42%) had no signs of SVD; 47 (19%) had from moderate to severe SVD burden. A total of 107 (42%) patients had no signs of SVD; 47 (19%) had from moderate to severe SVD burden. After adjustment, only TIMP-4 proved associations with SVD features. Brain atrophy was associated with baseline TIMP-4 (β = 0.20;p = 0.019) and leukoaraiosis with 90 days TIMP-4 (β = 0.19; p = 0.013). Global SVD score was not associated with baseline TIMP-4 levels (β = 0.10; p = 0.072), whereas was associated with 90 days TIMP-4 levels (β = 0.21; p = 0.003). Total SVD burden was associated with higher TIMP-4 levels 90 days after stroke, whereas was not during the acute phase. Our results support a biological relationship between SVD grade and TIMP-4.

Identifiants

pubmed: 29687301
doi: 10.1007/s12975-018-0627-x
pii: 10.1007/s12975-018-0627-x
doi:

Substances chimiques

TIMP1 protein, human 0
Tissue Inhibitor of Metalloproteinase-1 0
Tissue Inhibitor of Metalloproteinases 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-51

Références

Lancet. 2007 Jan 27;369(9558):275-82
pubmed: 17258667
Neurology. 2015 Feb 24;84(8):825-32
pubmed: 25632086
Neurobiol Aging. 2010 Dec;31(12):2128-35
pubmed: 19128858
Stroke. 2006 Jun;37(6):1391-8
pubmed: 16627790
FEBS Lett. 1997 Jan 20;401(2-3):213-7
pubmed: 9013889
Stroke. 1995 Jan;26(1):52-6
pubmed: 7839397
J Stroke Cerebrovasc Dis. 2017 Jul;26(7):1506-1513
pubmed: 28314624
Neurobiol Aging. 2012 Aug;33(8):1800-6
pubmed: 21601314
Neurology. 2017 Nov 21;89(21):2143-2150
pubmed: 29070665
Lancet Neurol. 2015 May;14(5):485-96
pubmed: 25819484
Int J Stroke. 2016 Jan;11(1):62-7
pubmed: 26763021
Neurology. 2014 Sep 30;83(14):1228-34
pubmed: 25165388
Stroke. 2013 Oct;44(10):2901-3
pubmed: 23908067
J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):192-7
pubmed: 19710048
J Cereb Blood Flow Metab. 1999 Jun;19(6):624-33
pubmed: 10366192
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Stroke. 2015 Jun;46(6):1554-60
pubmed: 25899244
Neuropathol Appl Neurobiol. 2007 Aug;33(4):410-9
pubmed: 17442062
Stroke. 2010 Feb;41(2):267-72
pubmed: 20044528
Acta Neurol Scand. 2017 Jul;136(1):72-77
pubmed: 28233290
Circulation. 2003 Feb 4;107(4):598-603
pubmed: 12566373
Stroke. 2014 Feb;45(2):605-7
pubmed: 24399375
Neurobiol Aging. 2015 Oct;36(10):2806-11
pubmed: 26189091
Stroke. 2001 May;32(5):1162-8
pubmed: 11340226
Lancet Neurol. 2013 May;12(5):483-97
pubmed: 23602162
Cerebrovasc Dis. 2015;40(3-4):157-64
pubmed: 26279056
J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1080-3
pubmed: 2292703
Stroke. 2011 May;42(5):1345-50
pubmed: 21454822
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
Stroke. 2009 Mar;40(3 Suppl):S20-3
pubmed: 19064797
Radiology. 2009 Oct;253(1):174-83
pubmed: 19635835
Stroke. 2003 Mar;34(3):806-12
pubmed: 12624314
Arch Neurol. 1999 Sep;56(9):1104-8
pubmed: 10488811
Hypertension. 2016 Jan;67(1):214-22
pubmed: 26597823
Br J Pharmacol. 2002 Dec;137(8):1330-8
pubmed: 12466243

Auteurs

Francesco Arba (F)

Department of NEUROFARBA, Neuroscience Section, University of Florence, Florence, Italy. francesco.arba@unifi.it.
Stroke Unit and Neurology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy. francesco.arba@unifi.it.

Benedetta Piccardi (B)

Department of NEUROFARBA, Neuroscience Section, University of Florence, Florence, Italy.
Stroke Unit and Neurology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Vanessa Palumbo (V)

Stroke Unit and Neurology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Betti Giusti (B)

Department of Experimental and Clinical Medicine, Atherothrombotic Diseases Center, AOU Careggi, University of Florence, Florence, Italy.

Patrizia Nencini (P)

Stroke Unit and Neurology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Anna Maria Gori (AM)

Department of Experimental and Clinical Medicine, Atherothrombotic Diseases Center, AOU Careggi, University of Florence, Florence, Italy.

Alice Sereni (A)

Department of Experimental and Clinical Medicine, Atherothrombotic Diseases Center, AOU Careggi, University of Florence, Florence, Italy.

Mascia Nesi (M)

Stroke Unit and Neurology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Giovanni Pracucci (G)

Department of NEUROFARBA, Neuroscience Section, University of Florence, Florence, Italy.

Giorgio Bono (G)

Stroke Unit, Department of Neurology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.

Paolo Bovi (P)

SSO Stroke Unit, Department of Neurosciences, Azienda Ospedaliera Integrata, Verona, Italy.

Enrico Fainardi (E)

Department of Neuroradiology, Careggi University Hospital, Florence, Italy.

Domenico Consoli (D)

U.O. Neurologia, G. Jazzolino Hospital, Vibo Valentia, Italy.

Antonia Nucera (A)

Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, ON, Canada.

Francesca Massaro (F)

Neurology Unit, Santo Stefano Hospital, Prato, Italy.

Giovanni Orlandi (G)

Department of Neurosciences, Neurological Clinic, University of Pisa, Pisa, Italy.

Francesco Perini (F)

UOC di Neurologia e Stroke Unit, Ospedale San Bortolo, Vicenza, Italy.

Rossana Tassi (R)

U.O.C. Stroke Unit, Dipartimento di Scienze Neurologiche e Neurosensoriali, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

Maria Sessa (M)

U.O. Neurologia, DAI Neuroscienze-Riabilitazione, Azienda Ospedaliera-Universitaria S. Anna, Ferrara, Italy.

Danilo Toni (D)

Emergency Department Stroke Unit, Department of Neurological Sciences, Sapienza University of Rome, Rome, Italy.

Rosanna Abbate (R)

Centro Studi Medicina Avanzata (CESMAV), Florence, Italy.

Domenico Inzitari (D)

Institute of Neuroscience, Italian National Research Council, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH